H. Yoshita

The comparison between UGT1A1 single heterozygous and wild-type regarding the clinical outcomes of fixed-dose irinotecan monotherapy for advanced gastric cancer: a multicenter retrospective study

Introduction Irinotecan is a key drug for advanced gastric cancer (AGC). We previously reported that patients with UGT1A1 single heterozygous (SH) had a significantly high frequency of s...

T. Miyagishima ;

A. Tanimoto ;

S. Yuki ;

T. Honda ;

Y. Komatsu ;

Y. Kobayashi ;

T. Sasaki ;

Y. Kawamoto ;

A. Ishiguro ;

K. Hatanaka ;

M. Dazai ;

H. Nakatsumi ;

Tomo Ando , MD;

H. Yoshita ;

S. Nakano ;

K. Sawada ;

T. Muranaka ;

K. Harada ;

07/01/2019

A phase II study of weekly paclitaxel in patients with advanced or recurrent esophageal cancer who had previously received docetaxel-containing chemotherapy

Background Both docetaxel and paclitaxel are a class of microtubule-stabilizing anticancer agents. Partial cross-resistance between docetaxel and paclitaxel was indicate...

K. Yoshimura ;

Tomo Ando , MD;

K. Nakashima ;

H. Yoshita ;

M. Sakumura ;

M. Nomura ;

M. Muto ;

Y. Horie ;

H. Takeda ;

T. Yoshii ;

Y. Tahara ;

C. Katada ;